緑内障の世界市場：2024年～2031年

概要

緑内障の世界市場は、2023年に83億6,000万米ドルに達し、2031年には127億7,000万米ドルに達すると予測され、予測期間2024年にはCAGR 5.5％で成長する見込みです。

緑内障は、視神経の損傷による進行性の視力低下と失明を特徴とする眼疾患群です。視神経は脳から眼球への信号伝達において重要な役割を果たしています。視神経の損傷は、眼球内の房水の過剰な蓄積によって引き起こされ、その結果眼圧が上昇し、最終的に視神経が損傷します。

世界の緑内障市場は、緑内障の普及率の増加によって牽引されています。例えば、緑内障調査財団によると、現在世界中で約8,000万人が緑内障に苦しんでいます。緑内障に苦しむ300万人以上のアメリカ人の約半数は、自分が緑内障であることに気づいていないです。

市場力学：

促進要因と阻害要因

緑内障の有病率の上昇

緑内障市場は、有病率の上昇に牽引され、予測期間中に有利な成長を遂げると予測されています。緑内障は主に60歳以上の高齢者に見られます。現在の世界人口は高齢化しており、高齢者はこの疾患を発症するリスクが高いです。例えば、緑内障調査財団によると、現在、全世界で約8,000万人の緑内障患者がおり、2040年までに約2,200万人が緑内障により失明するといいます。

同財団はまた、高齢化社会は緑内障を発症するリスクが高いとしています。国連によると、60歳以上の世界人口は2023年の11億4,000万人から2030年には14億2,000万人に達すると予想されています。National Center for Biotechnology Informationに掲載された疫学調査によると、2040年までに緑内障の世界人口は約1億1,200万人に達する可能性があります。

代替療法の利用可能性

緑内障の世界市場の成長は、代替療法の利用可能性の増加によって制約を受け、従来の外科的方法や標準的な薬物送達システムから需要がシフトしています。ジェネリック医薬品の選択肢の拡大は競合を激化させ、患者の嗜好の進化は従来の医薬品治療への固執をさらに困難にします。患者と医療提供者の双方が新たな治療法を模索する中、こうした代替療法への嗜好が、既に確立された緑内障医薬品や外科手術の成長性を制限する可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
  • 緑内障の普及率の上昇
  • 抑制要因
    • 代替療法の利用可能性
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• 償還分析
• 特許分析
• SWOT分析
• DMIの見解

第6章 タイプ別

• 開放隅角緑内障
• 角度閉鎖緑内障
• 先天性緑内障
• その他

第7章 治療タイプ別

• プロスタグランジン
• ベータ遮断薬
• アルファアドレナリン作動薬
• 炭酸脱水酵素阻害剤
• 縮瞳薬
• Rhoキナーゼ阻害剤
• インプラント
• その他

第8章 年齢層別

• 子供
• 大人
• 老年医学

第9章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第12章 企業プロファイル

• Novartis AG
  • 会社概要
  • 製品ポートフォリオと概要
  • 財務概要
  • 主な発展
• Bausch+Lomb.
• Viatris Inc.
• AbbVie.
• Alcon Inc.
• Thea Pharma Inc.
• Pfizer Inc.
• Santen Pharmaceutical Co., Ltd.
• Sun Pharmaceutical Industries, Inc.
• Somerset Pharma LLC

第13章 付録

Overview

The global glaucoma market reached US$ 8.36 billion in 2023 and is expected to reach US$ 12.77 billion by 2031, growing at a CAGR of 5.5% during the forecast period 2024-2031.

Glaucoma is a group of eye conditions characterized by progressive vision loss and blindness caused by damage to the optic nerve. The optic nerve plays a crucial role in relaying signals from the brain to the eye. The damage is caused by an excessive buildup of aqueous humor in the eye, which results in higher intraocular pressure and ultimately damages the optic nerve.

The global glaucoma market is driven by the increasing prevalence of glaucoma. For instance, according to the Glaucoma Research Foundation, approximately 80 million individuals worldwide suffer from glaucoma at present. About half of the more than 3 million Americans who suffer from glaucoma are unaware that they have the condition.

Market Dynamics: Drivers & Restraints

Rising prevalence of glaucoma

The market for Glaucoma is expected to attain lucrative growth in the forecast period, driven by the rising prevalence. Glaucoma is majorly seen in elderly people above 60 years of age. The current global population is aging and they are at a higher risk of developing the condition. For instance, according to the Glaucoma Research Foundation, there are approximately 80 million glaucoma patients worldwide at present, and by 2040, approximately 22 million individuals will be blind due to glaucoma.

The foundation also states that the aging population is at a higher risk of developing glaucoma. According to the United Nations, the global population above 60 years of age is expected to reach 1.42 billion in 2030 from 1.14 billion in 2023. As per an epidemiology study published in the National Center for Biotechnology Information, by 2040, the global population with glaucoma could account for approximately 112 million.As the prevalence rises, the demand for advanced therapeutics is anticipated to rise continuously driving the market growth.

Availability of alternate therapies

The growth of the global glaucoma market is constrained by the increasing availability of alternative therapies, which shifts demand away from traditional surgical methods and standard medication delivery systems. The expansion of generic options intensifies competition, while evolving patient preferences further challenge adherence to conventional pharmaceutical treatments. As both patients and healthcare providers explore new therapeutic options, the preference for these alternatives may limit the growth potential of established glaucoma drugs and surgical procedures.

Segment Analysis

The global glaucoma market is segmented based on type, treatment type, age group, distribution channel, and region.

Treatment Type:

Prostaglandins segment is expected to dominate the glaucoma market sharerostaglandins segment is expected to dominate the glaucoma market share due to their promising results in glaucoma treatment. In recent times, prostaglandins have evolved as a promising therapeutic class for glaucoma treatment. This prostaglandin class includes drugs like latanoprost, bimatoprost, travoprost, and others. These drugs decrease the intraocular pressure (IOP) in glaucoma by increasing the uveoscleral outflow. The built-up aqueous humor will be drained out and results in the reduction of pressure on the optic nerve.

These drugs have rapidly replaced beta blockers which were once the first-line agents for glaucoma. This rapid shift is primarily due to their efficacy, ease of usage, and limited adverse effect profile. Several research studies have concluded that prostaglandins are efficacious in reducing intra-ocular pressure, and at regular doses, there are little to no side effects. For instance, Moreover, manufacturers are focused on developing this class of medication, as they have proven their benefits in glaucoma treatment. For instance, in December 2024, the U.S. Food and Drug Administration (FDA) approved iDoseTR (travoprost intracameral implant) developed by Glaukos Corporation. iDoseTR is a long-duration intracameral therapy designed to continuously deliver prostaglandin at therapeutic levels.

Alpha-adrenergic agonists segment is the fastest growing segment in the glaucoma market share

The significant expansion of the alpha-adrenergic agonists segment in the glaucoma market can be attributed to their efficiency in lowering IOP, acceptable safety profile, increased prevalence of glaucoma, and advances in drug delivery techniques. As healthcare practitioners become more aware of the benefits of these drugs, their involvement in managing glaucoma is likely to grow, cementing their status as an important component of modern glaucoma management.

Type:

Open-angle glaucoma segment is expected to dominate the glaucoma market share

The open-angle glaucoma segment is expected to hold the dominant position in the glaucoma market share. This is due to the increasing incidence of open-angle glaucoma. Open-angle glaucoma is a chronic eye condition characterized by increased intraocular pressure, potentially leading to optic nerve damage and vision loss. As the most common type of glaucoma, it often develops gradually without noticeable symptoms until advanced stages.

For instance, according to the American Academy of Ophthalmology, in people older than 40 years old, the prevalence of primary open-angle glaucoma (POAG) is 1.86%. POAG prevalence is estimated to be highest among Chinese people, intermediate among Japanese, and lower among Europeans and Indians. In a rural East African population-based study, 3,268 underwent ophthalmic examination. POAG was diagnosed in 3.1%. A hospital-based survey of glaucomas in Ghana reported that the most common form of glaucoma was primary open-angle glaucoma (44.2%).

Angle-closure glaucoma segment is the fastest growing segment in the glaucoma market share

The angle-closure glaucoma segment is the fastest growing segment in the glaucoma market. The angle-closure glaucoma segment's rapid expansion in the glaucoma treatment market can be attributed to greater information about the ailment, advancements in treatment technology, and demographic shifts that result in higher prevalence rates. As healthcare systems adjust to address these problems, investments in research and development will most certainly continue to improve treatment choices available for angle-closure glaucoma.

Geographical Analysis

North America is expected to hold a significant position in the glaucoma market share

North America is expected to hold a significant portion of the global glaucoma market. North America is well known for its advanced healthcare industry. The higher expenditure on healthcare and rising awareness among people, advancement of technologies for glaucoma treatment, and increase in biopharmaceutical establishment across the region are the main factors contributing to the market growth in the region. Moreover, the market players majorly generate their revenue from the region, which is a major contributing factor to the region's dominance. For instance, AbbVie generated 432 USD million in 2023 for Lumigan (bimatoprost). Nearly 40% of this revenue is from the U.S. market. Moreover, the company generated 272 USD million in the same year for Alphagan a medication used to treat open-angle glaucoma. Among the total revenue, the company has generated approximately 45% from the U.S.

The availability of branded formulations in the U.S. and the revenue generated by the manufacturers act as a key contributor to the region's dominance. Moreover, the higher prevalence of glaucoma in the region is another factor contributing to market growth in the region. For instance, according to the Centers for Disease Control and Prevention (CDC), Glaucoma is one of the leading causes of blindness in the U.S. and the total prevalent cases account for approximately 3 million cases by 2050, these cases are expected to reach 6.3 million.

Asia Pacific is growing at the fastest pace in the glaucoma market

The Asia Pacific region's rapid increase in the worldwide glaucoma market can be attributed to a number of factors including rising prevalence rates, economic development resulting in greater healthcare access, technical breakthroughs in treatment approaches, and higher public awareness about eye health. As these variables continue to converge, Asia Pacific is projected to strengthen its position as a prominent participant in the global glaucoma treatment landscape.

Market Segmentation

By Type

• Open-Angle Glaucoma
• Angle-Closure Glaucoma
• Congenital Glaucoma
• Others

By Treatment Type

• Prostaglandins
  • Bimatoprost
  • Latanoprost
  • Travoprost
  • Others
• Beta Blockers
  • Timolol
  • Betaxolol
  • Others
• Alpha-Adrenergic Agonists
• Carbonic Anhydrase Inhibitors
• Miotics
• Rho Kinase Inhibitors
• Implants
• Others

By Age Group

• Children
• Adults
• Geriatrics

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the global glaucoma market include Novartis AG, Bausch + Lomb., Viatris Inc., AbbVie., Alcon Inc., Thea Pharma Inc., Pfizer Inc., Santen Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries, Inc., Somerset Pharma LLC among others.

Emerging Players

Metcela Inc., Inspira-Technologies OXY B.H.N. LTD., LIVANOVA PLC among others.

Key Developments

• In October 2024, Spinogenix, Inc., a clinical-stage biopharmaceutical company that pioneers first-in-class therapeutics that restore synapses to improve patients' lives worldwide, announced that it has brought world-leading clinical and research expertise in glaucoma to Spinogenix as the company prepares to launch a new program to evaluate SPG302 as a potential neuroprotective therapeutic for glaucoma. Spinogenix endorses SPG302 as a cutting-edge glaucoma treatment. SPG302 is a small molecule medication in clinical stage that is taken orally and has the unusual capacity to quickly rebuild glutamatergic synapses.

Why Purchase the Report?

• To visualize the global glaucoma market segmentation based on type, treatment type, age group, distribution channel, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of glaucoma market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global glaucoma market report would provide approximately 53 tables, 47 figures, and 176 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Treatment Type
• 3.3. Snippet by Age Group
• 3.4. Snippet by Distribution Channel
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
  • 4.1.2. Rising Prevalence of Glaucoma
  • 4.1.3. Restraints
    • 4.1.3.1. Availability of Alternate Therapies
  • 4.1.4. Opportunity
  • 4.1.5. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Reimbursement Analysis
• 5.6. Patent Analysis
• 5.7. SWOT Analysis
• 5.8. DMI Opinion

6. By Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 6.1.2. Market Attractiveness Index, By Type
• 6.2. Open-Angle Glaucoma*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Angle-Closure Glaucoma
• 6.4. Congenital Glaucoma
• 6.5. Others

7. By Treatment Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 7.1.2. Market Attractiveness Index, By Treatment Type
• 7.2. Prostaglandins*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Beta Blockers
• 7.4. Alpha-Adrenergic Agonists
• 7.5. Carbonic Anhydrase Inhibitors
• 7.6. Miotics
• 7.7. Rho Kinase Inhibitors
• 7.8. Implants
• 7.9. Others

8. By Age Group

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 8.1.2. Market Attractiveness Index, By Age Group
• 8.2. Children*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Adults
• 8.4. Geriatrics

9. By Distribution Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.1.2. Market Attractiveness Index, By Distribution Channel
• 9.2. Hospital Pharmacies*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Retail Pharmacies
• 9.4. Online Pharmacies

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.7.1. The U.S.
    • 10.2.7.2. Canada
    • 10.2.7.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.7.1. Germany
    • 10.3.7.2. UK
    • 10.3.7.3. France
    • 10.3.7.4. Italy
    • 10.3.7.5. Spain
    • 10.3.7.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.7.1. Brazil
    • 10.4.7.2. Argentina
    • 10.4.7.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.7.1. China
    • 10.5.7.2. India
    • 10.5.7.3. Japan
    • 10.5.7.4. South Korea
    • 10.5.7.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Novartis AG *
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Bausch + Lomb.
• 12.3. Viatris Inc.
• 12.4. AbbVie.
• 12.5. Alcon Inc.
• 12.6. Thea Pharma Inc.
• 12.7. Pfizer Inc.
• 12.8. Santen Pharmaceutical Co., Ltd.
• 12.9. Sun Pharmaceutical Industries, Inc.
• 12.10. Somerset Pharma LLC

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us